{"version":"1.0","provider_name":"Times South Africa","provider_url":"https:\/\/timessouthafrica.com","author_name":"TSA","author_url":"https:\/\/timessouthafrica.com\/author\/tsa\/","title":"Zenas BioPharma annonce qu\u2019un premier patient a re\u00e7u une dose dans le cadre d\u2019une \u00e9tude clinique de phase\u00a03 sur l\u2019ob\u00e9x\u00e9limab pour le traitement de la maladie li\u00e9e aux immunoglobulines\u00a0G4 (ML-IgG4) - Times South Africa","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"hWDvSOWS7P\"><a href=\"https:\/\/timessouthafrica.com\/zenas-biopharma-annonce-quun-premier-patient-a-recu-une-dose-dans-le-cadre-dune-etude-clinique-de-phase-3-sur-lobexelimab-pour-le-traitement-de-la-maladie-liee-aux-immu\/\">Zenas BioPharma annonce qu\u2019un premier patient a re\u00e7u une dose dans le cadre d\u2019une \u00e9tude clinique de phase\u00a03 sur l\u2019ob\u00e9x\u00e9limab pour le traitement de la maladie li\u00e9e aux immunoglobulines\u00a0G4 (ML-IgG4)<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/timessouthafrica.com\/zenas-biopharma-annonce-quun-premier-patient-a-recu-une-dose-dans-le-cadre-dune-etude-clinique-de-phase-3-sur-lobexelimab-pour-le-traitement-de-la-maladie-liee-aux-immu\/embed\/#?secret=hWDvSOWS7P\" width=\"600\" height=\"338\" title=\"&#8220;Zenas BioPharma annonce qu\u2019un premier patient a re\u00e7u une dose dans le cadre d\u2019une \u00e9tude clinique de phase\u00a03 sur l\u2019ob\u00e9x\u00e9limab pour le traitement de la maladie li\u00e9e aux immunoglobulines\u00a0G4 (ML-IgG4)&#8221; &#8212; Times South Africa\" data-secret=\"hWDvSOWS7P\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"La phase\u00a03 de l\u2019\u00e9tude mondiale INDIGO \u00e9valuera l\u2019efficacit\u00e9 et l\u2019innocuit\u00e9 de l\u2019ob\u00e9x\u00e9limab chez des patients atteints de la ML-IgG4, une maladie fibro-inflammatoire chronique et grave qui affecte g\u00e9n\u00e9ralement plusieurs organes La ML-IgG4 est la premi\u00e8re de plusieurs indications de maladies potentielles \u00e0 faire l\u2019objet de recherche pour l\u2019ob\u00e9x\u00e9limab compte tenu de son inhibition unique des [\u2026]","thumbnail_url":"https:\/\/ci5.googleusercontent.com\/proxy\/4TLR_imX-AIuQsE9kglz1X27LoYKRwq1dMVDTpMU5OCcOZmu0DE4dB3VpwjJXl5-mjQ9ZdK84-51LTeGxyu0BoGqp2DPLTIKAtAnO2WVbDWgXKgHLV0OVUcYSunX9DwECJQ2Ca3y0tOTLa_SRK0Q5SzCOKnYjJswvP1spzRiFtSWQWbt3xP3O010RPYiDX6mPAb12A=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/NjgwZDMzMTYtNGQ1My00NTQ3LTk4MGMtYzcxMDc2NTdiYjlhLTEyMTkzNDg=\/tiny\/Zenas-BioPharma-USA-LLC.png"}